Research programme: cannabis extract therapeutics - Cannabis Science

Drug Profile

Research programme: cannabis extract therapeutics - Cannabis Science

Alternative Names: CS-S/BCC-1; CS-TATI-1; Phytocannabinoid-based pharmaceutical products - Cannabis Science

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cannabis Science
  • Developer Cannabis Science; Italian Institute for Health and Science on Ageing
  • Class Antineoplastics; Cannabinoids; Skin disorder therapies
  • Mechanism of Action Cannabinoid receptor modulators; Human immunodeficiency virus tat gene product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Adult respiratory distress syndrome; Cancer; HIV infections; Kaposi's sarcoma; Pain; Post-traumatic stress disorders; Respiratory tract disorders; Skin cancer; Sleep disorders
  • Research Anxiety disorders; Attention-deficit hyperactivity disorder; Autistic disorder; Fibromyalgia; Neuropathic pain

Most Recent Events

  • 01 Dec 2017 Early research for Autistic-disorder is ongoing in USA (Cannabis Science Pipeline, December 2017)
  • 01 Dec 2017 Preclinical development in Adult-respiratory-distress-syndrome is ongoing in USA (PO, Lozenge) (Cannabis Science Pipeline, December 2017)
  • 01 Dec 2017 Preclinical development in Cancer is ongoing in USA (Cannabis Science Pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top